Clinicopathological Factors in Relation to HER2 Status in Metastatic Gastric Cancer: A Retrospective Observational Study
Received Date : 07 Oct 2021
Accepted Date : 15 Dec 2021
Available Online : 29 Dec 2021
Mustafa GÜRBÜZa, İzzet DOĞANb, Erman AKKUŞc, İbrahim KARADAĞd, Serdar KARAKAYAd,Cihan EROLe, Ramazan ACARf, Mert KARAOĞLANc, Elif Berna KÖKSOYa, Berna SAVAŞg, Mehmet Ali Nahit ŞENDURe, Didem TAŞTEKİNb, Nuri KARADURMUŞf, Ömür Berna ÇAKMAK ÖKSÜZOĞLUd, Filiz ÇAY ŞENLERa
aDivision of Medical Oncology, Ankara University Faculty of Medicine, Ankara, TURKEY
bDivision of Medical Oncology, İstanbul University Faculty of Medicine, İstanbul, TURKEY
cDepartment of Internal Medicine, Ankara University Faculty of Medicine, Ankara, TURKEY
dDivision of Medical Oncology, University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, TURKEY
eDivision of Medical Oncology, Yıldırım Beyazıt University Faculty of Medicine, Ankara, TURKEY
fDivision of Medical Oncology, University of Health Sciences Gülhane Training and Research Hospital, Ankara, TURKEY
gDepartment of Pathology, Ankara University Faculty of Medicine, Ankara, TURKEY
Doi: 10.37047/jos.2021-86554 - Article's Language: EN
J Oncol Sci. 2022;8(1):14-9
ABSTRACT
Objective: Data available on the rate of human epidermal growth factor receptor 2 (HER2) positivity and clinicopathological
parameters related to it are heterogeneous. Hence, it is pertinent to investigate these parameters in different populations. This study aims to
determine the frequency of HER2 positivity and clinicopathological factors associated with it in metastatic gastric cancer patients in a Turkish
population. Material and Methods: This study included 552 patients with metastatic gastric cancer from 5 oncology centers. HER2 status,
age, gender, smoking and alcohol history, body mass index, basal carcino embryonic antigen (CEA) level, basal cancer antigen 19-9 (CA
19-9) level, tumor localization, de-novo metastatic cancer, Lauren classification, signet-ring cell component, venous and neural invasion, and
histological grade data were collected retrospectively. HER2 positivity was defined as an immunohistochemistry (IHC) score of 3+ or an IHC
score of 2+ and in situ hybridization positive. Univariable and multivariable logistic regression analyses were used to detect clinicopathological
factors associated with HER2 status. Results: A total of 100 patients (18.1%) were HER2-positive. Alcohol consumption, basal CEA level,
basal CA 19-9 level, and signet-ring cell component were found to be statistically significant in univariable analysis. Alcohol use, basal CEA
level, and having signet-ring cell component were statistically significant in the multivariable analysis. Odds ratios of alcohol use, high basal
CEA and having signet-ring component were 2.35 (95% confidence interval (CI): 1.27-4.36, p=0.006), 1.99 (95% CI: 1.19-3.36, p=0.009),
and 0.39 (95% CI: 0.22-0.71, p=0.002) respectively. Conclusion: HER2 positivity was detected in 18.1% of metastatic gastric cancer patients
in the Turkish population. Alcohol use and basal CEA level were positively, and the signet-ring cell component was negatively correlated with
HER2 positivity.
Keywords: Gastric cancer; HER2; clinicopathological factors; ISH